Trial Profile
Japanese study to evaluate the utility of eribulin dose and schedule in treatment for advanced breast cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2018
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms JUST
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 03 Aug 2012 New trial record